Structure

InChI Key DGAIEPBNLOQYER-UHFFFAOYSA-N
Smile COCC(=O)Nc1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)N(C)CC(O)CO)c1I
InChI
InChI=1S/C18H24I3N3O8/c1-24(4-9(28)6-26)18(31)12-13(19)11(17(30)22-3-8(27)5-25)14(20)16(15(12)21)23-10(29)7-32-2/h8-9,25-28H,3-7H2,1-2H3,(H,22,30)(H,23,29)

Physicochemical Descriptors

Property Name Value
Molecular Formula C18H24I3N3O8
Molecular Weight 791.11
AlogP -0.41
Hydrogen Bond Acceptor 8.0
Hydrogen Bond Donor 6.0
Number of Rotational Bond 11.0
Polar Surface Area 168.66
Molecular species NEUTRAL
Aromatic Rings 1.0
Heavy Atoms 32.0

Experimental and Estimated Properties

Property Name Value Unit Method
log P (octanol-water) -2.05E+00 - EXP
Henry's Law Constant 1.00E-28 atm-m3/mole EST
Atmospheric OH Rate Constant 6.50E-11 cm3/molecule-sec EST
Water Solubility 23.8 mg/L EST
Vapor Pressure 1.59E-28 mm Hg EST

Pharmacology

Action Mechanism of Action Reference
None Diagnostic agent DailyMed

Indications

Mesh Heading Maximum Phase Reference
Coronary Artery Disease; Coronary Disease; Myocardial Ischemia Phase 4 ClinicalTrials
Infarction; Myocardial Infarction Phase 4 ClinicalTrials
Kidney Failure, Chronic; Renal Insufficiency Phase 4 ClinicalTrials
Hypothyroidism Phase 4 ClinicalTrials

Related Entries

MCS

Side Effects from Label

Adverse Reactions

System Organ Classification (SOC)
Relative Frequency (%)
Skin and subcutaneous tissue disorders
15.7
Respiratory, thoracic and mediastinal disorders
13.03
Immune system disorders
11.23
Nervous system disorders
9.65
Cardiac disorders
8.71
General disorders and administration site conditions
7.99
Vascular disorders
7.49
Gastrointestinal disorders
7.23
Injury, poisoning and procedural complications
3.36
Investigations
3.23
Eye disorders
2.88
Psychiatric disorders
2.35

Cross References

Resources Reference
CAS NUMBER 73334-07-3
ChEBI 63578
ChEMBL CHEMBL1725
DrugBank DB09156
DrugCentral 1468
EPA CompTox DTXSID0023163
FDA SRS 712BAC33MZ
Human Metabolome Database HMDB0041910
PubChem 3736
SureChEMBL SCHEMBL24546